{
    "organizations": [],
    "uuid": "3b90f4c06fcc27fe785405ce16d446919574223e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-alzinova-positive-initial-results/brief-alzinova-positive-initial-results-from-pre-study-with-alz-101-vaccine-idUSFWN1PX1C7",
    "ord_in_thread": 0,
    "title": "BRIEF-Alzinova: Positive Initial Results From Pre-Study With ALZ-101 Vaccine",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - ALZINOVA AB:\n* INITIAL RESULTS FROM PRE-STUDY WITH ALZ-101 VACCINE CONFIRM GOOD SAFETY PROFILE IN NON-HUMAN PRIMATES Source text: bit.ly/2EpNqX2 Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-07T23:27:00.000+02:00",
    "crawled": "2018-02-09T05:54:16.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "alzinova",
        "ab",
        "initial",
        "result",
        "vaccine",
        "confirm",
        "good",
        "safety",
        "profile",
        "primate",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}